OneMedNet (NASDAQ:ONMD) versus Medpace (NASDAQ:MEDP) Head-To-Head Contrast

Medpace (NASDAQ:MEDP) and OneMedNet (NASDAQ:ONMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Medpace and OneMedNet, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0	1	3	0	2.75
OneMedNet	0	0	0	0	N/A

Medpace currently has a consensus target price of $382.00, indicating a potential upside of 2.05%. Given Medpace’s higher possible upside, research analysts plainly believe Medpace is more favorable than OneMedNet.

Volatility & Risk

Medpace has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, OneMedNet has a beta of -0.55, indicating that its share price is 155% less volatile than the S&P 500.

Earnings & Valuation

This table compares Medpace and OneMedNet’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$1.89 billion	6.15	$282.81 million	$8.88	42.15
OneMedNet	$1.02 million	15.18	-$23.20 million	($0.19)	-3.42

Medpace has higher revenue and earnings than OneMedNet. OneMedNet is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medpace and OneMedNet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medpace	15.00%	63.98%	19.02%
OneMedNet	N/A	N/A	-116.74%

Institutional and Insider Ownership

78.0% of Medpace shares are held by institutional investors. Comparatively, 1.0% of OneMedNet shares are held by institutional investors. 20.3% of Medpace shares are held by company insiders. Comparatively, 45.7% of OneMedNet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Medpace beats OneMedNet on 11 of the 13 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

About OneMedNet

OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. The company is based in Eden Prairie, Minnesota.